Harvard Bioscience Charts New Course, Targeting Translational Science After Strong Financial Finish to 2025

HOLLISTON, Mass. – February 10, 2026 – Life science tools provider Harvard Bioscience, Inc. today announced a significant strategic pivot designed to capitalize on the rapidly growing translational science market, backed by strong preliminary fourth-quarter financial results and a positive outlook for 2026. The company is repositioning itself from a traditional tools supplier to a key enabler in bridging the gap between laboratory research and human clinical success.

The announcement pairs robust financial performance with a forward-looking strategy that leverages new product innovations and operational efficiencies. The company reported preliminary fourth-quarter 2025 revenue of $23.7 million and a gross margin of 60%, both at the high end of its guidance. More notably, it achieved a 27% year-over-year increase in adjusted EBITDA, signaling that recent cost-management initiatives are yielding substantial results.

A Financial Foundation for Growth

Harvard Bioscience's strategic realignment is built upon a newly stabilized financial base. The impressive preliminary Q4 2025 results suggest a significant turnaround for a company that has faced profitability challenges in recent years. The reported $23.7 million in revenue surpassed the midpoint of its guidance, while the 60% gross margin was attributed to a favorable mix of higher-margin products and the tangible benefits of prior cost-reduction efforts.

The 27% year-over-year surge in adjusted EBITDA to $3.8 million underscores a renewed focus on operational discipline. This financial strengthening is further supported by key structural changes, including a successful debt refinancing completed in December 2025 and a U.S. manufacturing consolidation announced in January 2026. These moves were designed to streamline operations, improve the balance sheet, and provide the necessary capital to fuel research and development.

Buoyed by this performance, the company has issued an optimistic forecast for the coming year, expecting year-over-year revenue growth and mid-to high-single-digit adjusted EBITDA growth in 2026. This financial momentum provides the crucial underpinning for its ambitious strategic shift.

"We’re pleased with our fourth quarter performance and excited to share an overview of our go-forward strategy," said John Duke, Chief Executive Officer. “With a stronger foundation provided by our refinancing and strategic consolidation, we’re scaling our business model by focusing our priorities on the evolving needs of the life sciences industry. We are excited for what’s ahead and are confident we will drive year over year revenue growth and mid-to high-single digit adjusted EBITDA growth in 2026.”

The Strategic Leap to Translational Science

The centerpiece of the announcement is Harvard Bioscience's evolution into a leader in translational science. This strategy aims to bridge the notorious gap between promising discoveries in preclinical research and their successful application in human therapies. The company plans to leverage its established, gold-standard position in preclinical tools to facilitate the industry's accelerating adoption of New Approach Methodologies (NAMs), particularly in the burgeoning fields of organoid and 3D biology.

This pivot aligns perfectly with a major industry trend. The market for human organoids—miniature, lab-grown organs that can mimic human biology—is projected to explode, with some analysts forecasting a compound annual growth rate (CAGR) of over 22% to reach nearly $6.3 billion by 2034. This growth is driven by intense demand for more accurate, ethical, and predictive models for drug discovery, which can reduce the costly late-stage failures and high reliance on traditional animal testing. By focusing on this space, Harvard Bioscience is positioning itself at the forefront of a paradigm shift in pharmaceutical research and development.

Innovating for the Future of Research

Driving this strategic shift is a pipeline of differentiated and innovative new products designed for modernizing preclinical and translational workflows. These platforms are not just incremental updates; they represent significant technological advancements aimed at solving critical research challenges.

One key innovation is the MeshMEA platform. Developed by its affiliate Multi Channel Systems, this unique microelectrode array features a thin, flexible mesh that allows researchers to record electrophysiological data from within a 3D organoid. This is a crucial advantage over traditional 2D arrays, which can flatten and compromise the complex structure of organoids. MeshMEA enables long-term studies while preserving the organoid's vital three-dimensional morphology, offering scientists unprecedented insight into the inner workings of these complex models.

Another core product, the SoHo™ telemetry platform, modernizes preclinical animal studies. This system uses small, implantable devices to continuously monitor physiological signals like ECG and EEG in freely moving, socially housed animals. By reducing experimental stress and allowing for more naturalistic observation, SoHo™ improves data quality and the translational relevance of preclinical safety and efficacy studies.

These products, along with specialized Incub8 platforms for tissue recording, form an integrated solution that supports researchers across critical stages of discovery, from early-stage organoid culture to advanced preclinical testing.

Building a Recurring Revenue Engine

Underpinning the company's growth strategy is a disciplined focus on its business model. Harvard Bioscience aims to significantly expand its proportion of high-margin consumables and software, with a clear goal of increasing its mix of recurring revenue from the current level of 55%.

This focus on consumables is a well-established path to financial stability and predictable earnings in the life science tools sector. As researchers adopt platforms like MeshMEA, they generate recurring demand for the proprietary microelectrode array chips and specialized culture media. This creates a virtuous cycle where instrument placements drive a long-tail of high-margin, repeatable sales.

The strategy is not just about selling more disposables; it's about creating an ecosystem where advanced instrumentation and essential consumables work together. This approach is designed to increase customer loyalty while building a more resilient and profitable business model that can consistently fund future innovation and strategic bolt-on acquisitions.